This is a multi-center randomized phase III clinical trial, the Inhibitor Eradication Trial,
in which Eloctate ITI plus Emicizumab will be compared with Eloctate ITI alone to eradicate
inhibitors in severe hemophilia A.
Phase:
Phase 3
Details
Lead Sponsor:
Margaret Ragni
Collaborator:
Health Resources and Services Administration (HRSA)